Theriva Biologics to Host a Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapies designed to treat cancer and related diseases in areas of high unmet need, today announced plans to host a conference call on Thursday, November 10, 2022 at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30 2022 and provide a company update.
People can participate in the live call by phone by dialing 1-888-254-3590 (domestic) or 1-929-477-0402 (international) and using conference ID: 5687287. Participants are asked to dial the number 15 minutes before the start of the call to register. Investors and the public can access the live and archived webcast of this call via the “News & Media” section of the Company’s website, https://www.therivabio.com, under “Events” or by clicking here , for 90 days after the appeal.
About Theriva Biologics, Inc.
Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company that develops therapeutic products designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary, VCN Biosciences, SL (VCN), has developed a novel oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumor administration to induce tumor cell death, enhance the access of co-administered cancer therapies to the tumor and promote a robust anti-tumor response supported by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus engineered to selectively and aggressively replicate in tumor cells and to degrade the tumor stromal barrier that serves as an important physical and immunosuppressive barrier in the treatment of cancer ; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics in the gastrointestinal (GI) tract to prevent damage to the microbiome, thereby limiting the overgrowth of pathogenic organisms such as VRE (vancomycin-resistant enterococci) and reducing the incidence and severity of acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic cell (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the intestinal alkaline phosphatase (IAP) enzyme produced under cGMP conditions and intended to treat both local gastrointestinal diseases and systemic diseases. For more information, please visit Theriva Biologics website at www.therivabio.com.
For more information, please contact:
LifeSci Advisors, LLC